Gossamer Bio, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $76.6M
- Price
- $0.1566
- % Change (Daily % change from the live per-ticker quote feed.)
- +9.43%
- Volume
- 6.9M
About
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Quick stats
Shares outstanding488.8M
Computed float453.6M
Float / shares92.8%
Cash runway (months)2.6
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001728117
Websitehttps://www.gossamerbio.com
AI Summary
AI-generated1/50
majorbullishearnings
Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update
Gossamer Bio remains on track to submit an NDA for seralutinib in PAH in September 2026 following a productive Pre-NDA Type B meeting with the FDA, where the agency characterized statistical significance issues as review rather than filing issues.
The company reacquired worldwide rights to seralutinib from Chiesi, dissolving the prior U.S. profit share and returning ex-U.S. rights to Gossamer in exchange for a capped royalty and milestone payments.
Gossamer also completed a convertible note exchange, reducing debt principal by approximately $115.9 million, and reported Q2 cash of $57.0 million.
Red flags
- Cash runway extends only into Q1 2027
- Stockholders authorized a reverse stock split, signaling potential listing compliance issues